Bone Marrow Plasma Cell Assessment before Peripheral Blood Stem Cell Mobilization in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation
The current definition of complete response (CR) in multiple myeloma (MM) includes negative serum and urine immunofixation (IFE) tests and
Gespeichert in:
| Veröffentlicht in: | BioMed research international 2014-01, Vol.2014 (2014), p.1-8 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 8 |
|---|---|
| container_issue | 2014 |
| container_start_page | 1 |
| container_title | BioMed research international |
| container_volume | 2014 |
| creator | Yoon, Jae-Ho Lee, Sung-Eun Shin, Seung-Hwan Eom, Ki-Seong Kim, Yoo-Jin Kim, Hee-Je Lee, Seok Cho, Seok-Goo Lee, Jong Wook Min, Woo-Sung Park, Chong-Won Kim, Myungshin Min, Chang-Ki |
| description | The current definition of complete response (CR) in multiple myeloma (MM) includes negative serum and urine immunofixation (IFE) tests and |
| doi_str_mv | 10.1155/2014/982504 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4033341</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A427025256</galeid><sourcerecordid>A427025256</sourcerecordid><originalsourceid>FETCH-LOGICAL-c527t-20adcb24e4b8344af10742a9a4f457065674f7882315247f85fb04a9acf6ee223</originalsourceid><addsrcrecordid>eNqNkk1vEzEQhlcIRKvQE2eQJS4IFOqP8X5ckNKIL6kRkWjPlnczm7jy2qm9S9T-nf5RHLaEwgV88Ujz-J15x5Nlzxl9x5iUp5wyOK1KLik8yo65YDDNGbDHh1iIo-wkxiuaTslyWuVPsyMOZSVzUR1nd2feIVnoEPyOLK2OnSZztJbMYsQYO3Q9qbH1AckSg9luMGhLzqz3K_Ktx26EF7421tzq3nhHjCPLFKWXkexMvyGLwfZma1OZG7Q-Fbh0Kwxrb9yazIbeW7_2Q3wgdxG0i1urXf9T8Vn2pNU24sn9PckuP364mH-enn_99GU-O582khf9lFO9amoOCHUpAHTLaAFcVxpakAXNZV5AW5RlGozkULSlbGsKKd-0OSLnYpK9H3W3Q93hqkkOklm1DabT4UZ5bdSfGWc2au2_K6BCCGBJ4PW9QPDXA8ZedSY2yZF2mBwqJvO8hDR5-A9U8AoqkPu2Xv2FXvkhuDSJREFRcagK-E2ttUVlXOtTi81eVM2AF5RLnn58kr0dqSb4GAO2B3eMqv1Cqf1CqXGhEv3y4UAO7K_1ScCbEdgYt9I78w-1FyOMCcFWH2DJBFAqfgA47NzO</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1547924974</pqid></control><display><type>article</type><title>Bone Marrow Plasma Cell Assessment before Peripheral Blood Stem Cell Mobilization in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation</title><source>MEDLINE</source><source>PubMed Central Open Access</source><source>Wiley Online Library Open Access</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Yoon, Jae-Ho ; Lee, Sung-Eun ; Shin, Seung-Hwan ; Eom, Ki-Seong ; Kim, Yoo-Jin ; Kim, Hee-Je ; Lee, Seok ; Cho, Seok-Goo ; Lee, Jong Wook ; Min, Woo-Sung ; Park, Chong-Won ; Kim, Myungshin ; Min, Chang-Ki</creator><contributor>Lee, Dong Soon</contributor><creatorcontrib>Yoon, Jae-Ho ; Lee, Sung-Eun ; Shin, Seung-Hwan ; Eom, Ki-Seong ; Kim, Yoo-Jin ; Kim, Hee-Je ; Lee, Seok ; Cho, Seok-Goo ; Lee, Jong Wook ; Min, Woo-Sung ; Park, Chong-Won ; Kim, Myungshin ; Min, Chang-Ki ; Lee, Dong Soon</creatorcontrib><description><![CDATA[The current definition of complete response (CR) in multiple myeloma (MM) includes negative serum and urine immunofixation (IFE) tests and <5% bone marrow plasma cells (BMPCs). However, many studies of the prognostic impact of pretransplant response have not included BMPCs. We evaluated the prognostic impact of BMPC assessment before peripheral blood stem cell (PBSC) mobilization on subsequent transplant outcomes. BMPCs were assessed by CD138, kappa, and lambda immunostaining in 106 patients. After a median followup of 24.5 months, patients with <5% BMPCs had a significantly better progression-free survival (PFS) compared to those with ≥5% BMPCs (P=0.005). Patients with <5% BMPCs + serologic CR showed superior PFS compared to those with <5% BMPCs + serologic non-CR (P=0.050) or ≥5% BMPCs + serologic non-CR (P=0.001). Interestingly, the prognostic impact of BMPCs was more apparent for patients who did not achieve a serologic CR (P=0.042) compared to those with a serologic CR (P=0.647). We concluded that IFE negativity and <5% BMPCs before PBSC mobilization were important factors to predict PFS in patients with MM undergoing ASCT. Particularly, a significant impact of <5% BMPCs was observed in patients who did not achieve IFE negativity.]]></description><identifier>ISSN: 2314-6133</identifier><identifier>EISSN: 2314-6141</identifier><identifier>DOI: 10.1155/2014/982504</identifier><identifier>PMID: 24895639</identifier><language>eng</language><publisher>Cairo, Egypt: Hindawi Puplishing Corporation</publisher><subject>Adult ; Aged ; Biomedical research ; Bone marrow ; Bone Marrow Cells - cytology ; Care and treatment ; Chemotherapy ; Complications and side effects ; Disease-Free Survival ; Female ; Hematopoietic Stem Cell Mobilization ; Hematopoietic Stem Cell Transplantation ; Humans ; Male ; Middle Aged ; Multiple myeloma ; Multiple Myeloma - therapy ; Multivariate Analysis ; Plasma ; Plasma Cells - metabolism ; Prognosis ; Stem cell research ; Stem cells ; Syndecan-1 - metabolism ; Transplantation ; Transplantation, Autologous ; Transplants & implants ; Treatment Outcome</subject><ispartof>BioMed research international, 2014-01, Vol.2014 (2014), p.1-8</ispartof><rights>Copyright © 2014 Sung-Eun Lee et al.</rights><rights>COPYRIGHT 2014 John Wiley & Sons, Inc.</rights><rights>Copyright © 2014 Sung-Eun Lee et al. Sung-Eun Lee et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</rights><rights>Copyright © 2014 Sung-Eun Lee et al. 2014</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c527t-20adcb24e4b8344af10742a9a4f457065674f7882315247f85fb04a9acf6ee223</citedby><cites>FETCH-LOGICAL-c527t-20adcb24e4b8344af10742a9a4f457065674f7882315247f85fb04a9acf6ee223</cites><orcidid>0000-0002-9810-2050 ; 0000-0003-2949-4166 ; 0000-0003-4098-3366 ; 0000-0002-0578-126X ; 0000-0001-8632-0168</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4033341/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4033341/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24895639$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Lee, Dong Soon</contributor><creatorcontrib>Yoon, Jae-Ho</creatorcontrib><creatorcontrib>Lee, Sung-Eun</creatorcontrib><creatorcontrib>Shin, Seung-Hwan</creatorcontrib><creatorcontrib>Eom, Ki-Seong</creatorcontrib><creatorcontrib>Kim, Yoo-Jin</creatorcontrib><creatorcontrib>Kim, Hee-Je</creatorcontrib><creatorcontrib>Lee, Seok</creatorcontrib><creatorcontrib>Cho, Seok-Goo</creatorcontrib><creatorcontrib>Lee, Jong Wook</creatorcontrib><creatorcontrib>Min, Woo-Sung</creatorcontrib><creatorcontrib>Park, Chong-Won</creatorcontrib><creatorcontrib>Kim, Myungshin</creatorcontrib><creatorcontrib>Min, Chang-Ki</creatorcontrib><title>Bone Marrow Plasma Cell Assessment before Peripheral Blood Stem Cell Mobilization in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation</title><title>BioMed research international</title><addtitle>Biomed Res Int</addtitle><description><![CDATA[The current definition of complete response (CR) in multiple myeloma (MM) includes negative serum and urine immunofixation (IFE) tests and <5% bone marrow plasma cells (BMPCs). However, many studies of the prognostic impact of pretransplant response have not included BMPCs. We evaluated the prognostic impact of BMPC assessment before peripheral blood stem cell (PBSC) mobilization on subsequent transplant outcomes. BMPCs were assessed by CD138, kappa, and lambda immunostaining in 106 patients. After a median followup of 24.5 months, patients with <5% BMPCs had a significantly better progression-free survival (PFS) compared to those with ≥5% BMPCs (P=0.005). Patients with <5% BMPCs + serologic CR showed superior PFS compared to those with <5% BMPCs + serologic non-CR (P=0.050) or ≥5% BMPCs + serologic non-CR (P=0.001). Interestingly, the prognostic impact of BMPCs was more apparent for patients who did not achieve a serologic CR (P=0.042) compared to those with a serologic CR (P=0.647). We concluded that IFE negativity and <5% BMPCs before PBSC mobilization were important factors to predict PFS in patients with MM undergoing ASCT. Particularly, a significant impact of <5% BMPCs was observed in patients who did not achieve IFE negativity.]]></description><subject>Adult</subject><subject>Aged</subject><subject>Biomedical research</subject><subject>Bone marrow</subject><subject>Bone Marrow Cells - cytology</subject><subject>Care and treatment</subject><subject>Chemotherapy</subject><subject>Complications and side effects</subject><subject>Disease-Free Survival</subject><subject>Female</subject><subject>Hematopoietic Stem Cell Mobilization</subject><subject>Hematopoietic Stem Cell Transplantation</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Multiple myeloma</subject><subject>Multiple Myeloma - therapy</subject><subject>Multivariate Analysis</subject><subject>Plasma</subject><subject>Plasma Cells - metabolism</subject><subject>Prognosis</subject><subject>Stem cell research</subject><subject>Stem cells</subject><subject>Syndecan-1 - metabolism</subject><subject>Transplantation</subject><subject>Transplantation, Autologous</subject><subject>Transplants & implants</subject><subject>Treatment Outcome</subject><issn>2314-6133</issn><issn>2314-6141</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>RHX</sourceid><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNqNkk1vEzEQhlcIRKvQE2eQJS4IFOqP8X5ckNKIL6kRkWjPlnczm7jy2qm9S9T-nf5RHLaEwgV88Ujz-J15x5Nlzxl9x5iUp5wyOK1KLik8yo65YDDNGbDHh1iIo-wkxiuaTslyWuVPsyMOZSVzUR1nd2feIVnoEPyOLK2OnSZztJbMYsQYO3Q9qbH1AckSg9luMGhLzqz3K_Ktx26EF7421tzq3nhHjCPLFKWXkexMvyGLwfZma1OZG7Q-Fbh0Kwxrb9yazIbeW7_2Q3wgdxG0i1urXf9T8Vn2pNU24sn9PckuP364mH-enn_99GU-O582khf9lFO9amoOCHUpAHTLaAFcVxpakAXNZV5AW5RlGozkULSlbGsKKd-0OSLnYpK9H3W3Q93hqkkOklm1DabT4UZ5bdSfGWc2au2_K6BCCGBJ4PW9QPDXA8ZedSY2yZF2mBwqJvO8hDR5-A9U8AoqkPu2Xv2FXvkhuDSJREFRcagK-E2ttUVlXOtTi81eVM2AF5RLnn58kr0dqSb4GAO2B3eMqv1Cqf1CqXGhEv3y4UAO7K_1ScCbEdgYt9I78w-1FyOMCcFWH2DJBFAqfgA47NzO</recordid><startdate>20140101</startdate><enddate>20140101</enddate><creator>Yoon, Jae-Ho</creator><creator>Lee, Sung-Eun</creator><creator>Shin, Seung-Hwan</creator><creator>Eom, Ki-Seong</creator><creator>Kim, Yoo-Jin</creator><creator>Kim, Hee-Je</creator><creator>Lee, Seok</creator><creator>Cho, Seok-Goo</creator><creator>Lee, Jong Wook</creator><creator>Min, Woo-Sung</creator><creator>Park, Chong-Won</creator><creator>Kim, Myungshin</creator><creator>Min, Chang-Ki</creator><general>Hindawi Puplishing Corporation</general><general>Hindawi Publishing Corporation</general><general>John Wiley & Sons, Inc</general><general>Hindawi Limited</general><scope>ADJCN</scope><scope>AHFXO</scope><scope>RHU</scope><scope>RHW</scope><scope>RHX</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7QO</scope><scope>7T7</scope><scope>7TK</scope><scope>7U7</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>CWDGH</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-9810-2050</orcidid><orcidid>https://orcid.org/0000-0003-2949-4166</orcidid><orcidid>https://orcid.org/0000-0003-4098-3366</orcidid><orcidid>https://orcid.org/0000-0002-0578-126X</orcidid><orcidid>https://orcid.org/0000-0001-8632-0168</orcidid></search><sort><creationdate>20140101</creationdate><title>Bone Marrow Plasma Cell Assessment before Peripheral Blood Stem Cell Mobilization in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation</title><author>Yoon, Jae-Ho ; Lee, Sung-Eun ; Shin, Seung-Hwan ; Eom, Ki-Seong ; Kim, Yoo-Jin ; Kim, Hee-Je ; Lee, Seok ; Cho, Seok-Goo ; Lee, Jong Wook ; Min, Woo-Sung ; Park, Chong-Won ; Kim, Myungshin ; Min, Chang-Ki</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c527t-20adcb24e4b8344af10742a9a4f457065674f7882315247f85fb04a9acf6ee223</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Biomedical research</topic><topic>Bone marrow</topic><topic>Bone Marrow Cells - cytology</topic><topic>Care and treatment</topic><topic>Chemotherapy</topic><topic>Complications and side effects</topic><topic>Disease-Free Survival</topic><topic>Female</topic><topic>Hematopoietic Stem Cell Mobilization</topic><topic>Hematopoietic Stem Cell Transplantation</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Multiple myeloma</topic><topic>Multiple Myeloma - therapy</topic><topic>Multivariate Analysis</topic><topic>Plasma</topic><topic>Plasma Cells - metabolism</topic><topic>Prognosis</topic><topic>Stem cell research</topic><topic>Stem cells</topic><topic>Syndecan-1 - metabolism</topic><topic>Transplantation</topic><topic>Transplantation, Autologous</topic><topic>Transplants & implants</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yoon, Jae-Ho</creatorcontrib><creatorcontrib>Lee, Sung-Eun</creatorcontrib><creatorcontrib>Shin, Seung-Hwan</creatorcontrib><creatorcontrib>Eom, Ki-Seong</creatorcontrib><creatorcontrib>Kim, Yoo-Jin</creatorcontrib><creatorcontrib>Kim, Hee-Je</creatorcontrib><creatorcontrib>Lee, Seok</creatorcontrib><creatorcontrib>Cho, Seok-Goo</creatorcontrib><creatorcontrib>Lee, Jong Wook</creatorcontrib><creatorcontrib>Min, Woo-Sung</creatorcontrib><creatorcontrib>Park, Chong-Won</creatorcontrib><creatorcontrib>Kim, Myungshin</creatorcontrib><creatorcontrib>Min, Chang-Ki</creatorcontrib><collection>الدوريات العلمية والإحصائية - e-Marefa Academic and Statistical Periodicals</collection><collection>معرفة - المحتوى العربي الأكاديمي المتكامل - e-Marefa Academic Complete</collection><collection>Hindawi Publishing Complete</collection><collection>Hindawi Publishing Subscription Journals</collection><collection>Hindawi Publishing Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Neurosciences Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies & Aerospace Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>Middle East & Africa Database</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Advanced Technologies & Aerospace Database</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>BioMed research international</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yoon, Jae-Ho</au><au>Lee, Sung-Eun</au><au>Shin, Seung-Hwan</au><au>Eom, Ki-Seong</au><au>Kim, Yoo-Jin</au><au>Kim, Hee-Je</au><au>Lee, Seok</au><au>Cho, Seok-Goo</au><au>Lee, Jong Wook</au><au>Min, Woo-Sung</au><au>Park, Chong-Won</au><au>Kim, Myungshin</au><au>Min, Chang-Ki</au><au>Lee, Dong Soon</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Bone Marrow Plasma Cell Assessment before Peripheral Blood Stem Cell Mobilization in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation</atitle><jtitle>BioMed research international</jtitle><addtitle>Biomed Res Int</addtitle><date>2014-01-01</date><risdate>2014</risdate><volume>2014</volume><issue>2014</issue><spage>1</spage><epage>8</epage><pages>1-8</pages><issn>2314-6133</issn><eissn>2314-6141</eissn><abstract><![CDATA[The current definition of complete response (CR) in multiple myeloma (MM) includes negative serum and urine immunofixation (IFE) tests and <5% bone marrow plasma cells (BMPCs). However, many studies of the prognostic impact of pretransplant response have not included BMPCs. We evaluated the prognostic impact of BMPC assessment before peripheral blood stem cell (PBSC) mobilization on subsequent transplant outcomes. BMPCs were assessed by CD138, kappa, and lambda immunostaining in 106 patients. After a median followup of 24.5 months, patients with <5% BMPCs had a significantly better progression-free survival (PFS) compared to those with ≥5% BMPCs (P=0.005). Patients with <5% BMPCs + serologic CR showed superior PFS compared to those with <5% BMPCs + serologic non-CR (P=0.050) or ≥5% BMPCs + serologic non-CR (P=0.001). Interestingly, the prognostic impact of BMPCs was more apparent for patients who did not achieve a serologic CR (P=0.042) compared to those with a serologic CR (P=0.647). We concluded that IFE negativity and <5% BMPCs before PBSC mobilization were important factors to predict PFS in patients with MM undergoing ASCT. Particularly, a significant impact of <5% BMPCs was observed in patients who did not achieve IFE negativity.]]></abstract><cop>Cairo, Egypt</cop><pub>Hindawi Puplishing Corporation</pub><pmid>24895639</pmid><doi>10.1155/2014/982504</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0002-9810-2050</orcidid><orcidid>https://orcid.org/0000-0003-2949-4166</orcidid><orcidid>https://orcid.org/0000-0003-4098-3366</orcidid><orcidid>https://orcid.org/0000-0002-0578-126X</orcidid><orcidid>https://orcid.org/0000-0001-8632-0168</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2314-6133 |
| ispartof | BioMed research international, 2014-01, Vol.2014 (2014), p.1-8 |
| issn | 2314-6133 2314-6141 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4033341 |
| source | MEDLINE; PubMed Central Open Access; Wiley Online Library Open Access; PubMed Central; Alma/SFX Local Collection |
| subjects | Adult Aged Biomedical research Bone marrow Bone Marrow Cells - cytology Care and treatment Chemotherapy Complications and side effects Disease-Free Survival Female Hematopoietic Stem Cell Mobilization Hematopoietic Stem Cell Transplantation Humans Male Middle Aged Multiple myeloma Multiple Myeloma - therapy Multivariate Analysis Plasma Plasma Cells - metabolism Prognosis Stem cell research Stem cells Syndecan-1 - metabolism Transplantation Transplantation, Autologous Transplants & implants Treatment Outcome |
| title | Bone Marrow Plasma Cell Assessment before Peripheral Blood Stem Cell Mobilization in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T23%3A03%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Bone%20Marrow%20Plasma%20Cell%20Assessment%20before%20Peripheral%20Blood%20Stem%20Cell%20Mobilization%20in%20Patients%20with%20Multiple%20Myeloma%20Undergoing%20Autologous%20Stem%20Cell%20Transplantation&rft.jtitle=BioMed%20research%20international&rft.au=Yoon,%20Jae-Ho&rft.date=2014-01-01&rft.volume=2014&rft.issue=2014&rft.spage=1&rft.epage=8&rft.pages=1-8&rft.issn=2314-6133&rft.eissn=2314-6141&rft_id=info:doi/10.1155/2014/982504&rft_dat=%3Cgale_pubme%3EA427025256%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1547924974&rft_id=info:pmid/24895639&rft_galeid=A427025256&rfr_iscdi=true |